Abstract 1807P
Background
Small cell lung cancer (SCLC) presents as a highly aggressive malignancy characterized by early dissemination and a grim long-term prognosis. The tumor boundary is a niche composed of malignant cells in the outermost circle of solid tumors and non-malignant cells closely adjacent in spatial architecture. Cell composition of the tumor boundary profoundly affects tumor microenvironment remodeling, which remains unexplored in SCLC.
Methods
We conducted spatial transcriptome sequencing of 10X Genomics Visium on 21 formalin-fixed paraffin-embedding samples of SCLC patients. Two pathologists performed the pathological annotations. We manually delineated the tumor regions using the 10X-developed Loupe software and defined the tumor boundary as the nearest 2-spot width area near the outermost circle of the tumor area. Then we compared the differentially expressed genes (DEGs) and enriched pathways between tumor boundary and tumor cores.
Results
21 samples yielded more than 100,000 spots with 18025 genes in our study. The tumor boundary exhibited heightened proliferation and angiogenesis activities. Notably, we identified MMP7 as a potential biomarker for tumor boundary, which was also found to be highly expressed in tumor-invasive areas. Furthermore, transcription factors SOX10, ZEB1, and SNAI2 exhibited enhanced expression in tumor boundaries, which promoted tumor proliferation, migration, and epithelial-mesenchymal transition. High expression levels of MMP7 were associated with poorer survival outcomes. Importantly, our findings unveiled the ability of MMP7 to recruit immunosuppressive MRC1+ macrophages. Additionally, we observed elevated expression of numerous immune checkpoints, including HAVCR2 and TIGHT, in this microenvironment, indicating immune resistance.
Conclusions
This study revealed MMP7 as the biomarker of tumor boundary correlated with immune resistance in SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1813TiP - Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study
Presenter: Valentina Gambardella
Session: Poster session 07
2P - Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma
Presenter: Alexander Lozano
Session: Poster session 07
3P - Metabolic reprogramming induced by KEAP1 mutation in NSCLC
Presenter: Renata Akhmetzianova
Session: Poster session 07
4P - CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
Presenter: Luisa Chocarro
Session: Poster session 07
5P - Circulating tumor cell-derived organoids from lung adenocarcinoma patients for assessment of EGFR and KRAS mutations
Presenter: Mohamed Lahmadi
Session: Poster session 07
6P - Circulating low-density neutrophils (LDNs) are associated with resistance to immunotherapy as frontline treatment for non-small cell lung cancer (NSCLC): Updated results and proteomic characterization
Presenter: Natalia Castro Unanua
Session: Poster session 07
7P - Association study between genetic variants in regulatory gene for RNA modification and prognosis in non-small cell lung cancer
Presenter: Eungbae Lee
Session: Poster session 07
8P - Profiling of zidesamtinib and other ROS1 inhibitors in an intracranial CD74-ROS1 G2032R preclinical model
Presenter: ANUPONG TANGPEERACHAIKUL
Session: Poster session 07
9P - Small-extracellular vesicles derived from NSCLC cells dampen the CD8+ T cell response against tumor
Presenter: Manon CHANG
Session: Poster session 07
10P - Multivariate analysis of functional organoid assays predicts patient responses in the clinic for colorectal and pancreatic cancer
Presenter: Anna-Rose Gryspeert
Session: Poster session 07